应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
HURA TuHURA Biosciences, Inc.
盘前交易 12-16 09:01:18 EST
0.9634
-0.0616
-6.01%
盘前
0.9400
-0.0234
-2.43%
08:12 EST
最高
1.03
最低
0.9300
成交量
86.59万
今开
1.03
昨收
1.03
日振幅
9.76%
总市值
5,850万
流通市值
5,230万
总股本
6,072万
成交额
84.88万
换手率
1.60%
流通股本
5,429万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Tuhura Biosciences发布Kintara的应急价值权(CVR),因Kintara的Rem-001达到了主要安全目标,实现合同里程碑
美股速递 · 12-15 20:50
Tuhura Biosciences发布Kintara的应急价值权(CVR),因Kintara的Rem-001达到了主要安全目标,实现合同里程碑
Tuhura Biosciences展示数据显示,Delta阿片受体(Dor)作为克服对免疫检查点抑制剂获得性耐药的新靶点,亮相第57届ASH年会暨博览会
美股速递 · 12-08
Tuhura Biosciences展示数据显示,Delta阿片受体(Dor)作为克服对免疫检查点抑制剂获得性耐药的新靶点,亮相第57届ASH年会暨博览会
Tuhura Biosciences Inc申请最高2.5亿美元的混合货架注册
投资观察 · 11-20
Tuhura Biosciences Inc申请最高2.5亿美元的混合货架注册
Tuhura Biosciences Inc:与H.C. Wainwright签订Atm协议以出售高达5000万美元的普通股
美股速递 · 11-04
Tuhura Biosciences Inc:与H.C. Wainwright签订Atm协议以出售高达5000万美元的普通股
TuHURA Biosciences(HURA.US)获HC Wainwright & Co.首次覆盖,给予买入评级, 目标价13.00美元。
金融界 · 03-03
TuHURA Biosciences(HURA.US)获HC Wainwright & Co.首次覆盖,给予买入评级, 目标价13.00美元。
暂无数据
公司概况
公司名称:
TuHURA Biosciences, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
TuHURA Biosciences, Inc.是一家内华达州公司,成立于2009年6月24日,名称为Berry Only,Inc。该公司是一家临床阶段的生物制药公司。Kintara致力于为医疗需求未得到满足的患者开发新型癌症疗法。Kintara公司正在开发两种晚期疗法,以降低风险,满足明确的未满足的医疗需求。这两个项目分别是VAL-083治疗胶质母细胞瘤(GBM)和REM-001治疗皮肤转移性乳腺癌(CMBC)。
发行价格:
--
{"stockData":{"symbol":"HURA","market":"US","secType":"STK","nameCN":"TuHURA Biosciences, Inc.","latestPrice":0.9634,"timestamp":1765832400000,"preClose":1.025,"halted":0,"volume":865911,"hourTrading":{"tag":"盘前","latestPrice":0.94,"preClose":0.9634,"latestTime":"08:12 EST","volume":259,"amount":243.5102201,"timestamp":1765890740034},"delay":0,"floatShares":54286373,"shares":60720500,"eps":-0.662671,"marketStatus":"盘前交易","change":-0.0616,"latestTime":"12-16 09:01:18 EST","open":1.03,"high":1.03,"low":0.93,"amount":848777.9983629,"amplitude":0.097561,"askPrice":1.04,"askSize":100,"bidPrice":0.931,"bidSize":800,"shortable":3,"etf":0,"ttmEps":-0.662671,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765895400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.9634,"preHourTrading":{"tag":"盘前","latestPrice":0.94,"preClose":0.9634,"latestTime":"08:12 EST","volume":259,"amount":243.5102201,"timestamp":1765890740034},"postHourTrading":{"tag":"盘后","latestPrice":0.9632,"preClose":0.9634,"latestTime":"19:50 EST","volume":5286,"amount":5119.3442,"timestamp":1765846241883},"volumeRatio":0.6720406990766149},"requestUrl":"/m/hq/s/HURA/tweets","defaultTab":"tweets","newsList":[{"id":"1150512948","title":"Tuhura Biosciences发布Kintara的应急价值权(CVR),因Kintara的Rem-001达到了主要安全目标,实现合同里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1150512948","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150512948?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:50","pubTimestamp":1765803053,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences发布Kintara的应急价值权(CVR),因Kintara的Rem-001达到了主要安全目标,实现合同里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"1183862465","title":"Tuhura Biosciences展示数据显示,Delta阿片受体(Dor)作为克服对免疫检查点抑制剂获得性耐药的新靶点,亮相第57届ASH年会暨博览会","url":"https://stock-news.laohu8.com/highlight/detail?id=1183862465","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183862465?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:51","pubTimestamp":1765198302,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences展示数据显示,Delta阿片受体(Dor)作为克服对免疫检查点抑制剂获得性耐药的新靶点,亮相第57届ASH年会暨博览会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"1115688327","title":"Tuhura Biosciences Inc申请最高2.5亿美元的混合货架注册","url":"https://stock-news.laohu8.com/highlight/detail?id=1115688327","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115688327?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:31","pubTimestamp":1763569873,"startTime":"0","endTime":"0","summary":"11月4日 - TuHURA Biosciences Inc宣布,已向SEC提交申请,计划进行最高达2.5亿美元的混合货架注册。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"1152480810","title":"Tuhura Biosciences Inc:与H.C. Wainwright签订Atm协议以出售高达5000万美元的普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1152480810","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152480810?lang=zh_cn&edition=full","pubTime":"2025-11-04 20:23","pubTimestamp":1762259005,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences Inc:与H.C. Wainwright签订Atm协议以出售高达5000万美元的普通股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2516049635","title":"TuHURA Biosciences(HURA.US)获HC Wainwright & Co.首次覆盖,给予买入评级, 目标价13.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516049635","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516049635?lang=zh_cn&edition=full","pubTime":"2025-03-03 21:20","pubTimestamp":1741008040,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences(HURA.US)获HC Wainwright & Co.首次覆盖,给予买入评级, 目标价13.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03212048493051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HURA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintara.com","stockEarnings":[{"period":"1week","weight":-0.5134},{"period":"1month","weight":-0.53},{"period":"3month","weight":-0.6115},{"period":"6month","weight":-0.6432},{"period":"1year","weight":-0.8046},{"period":"ytd","weight":-0.7644}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0314},{"period":"6month","weight":0.1394},{"period":"1year","weight":0.1266},{"period":"ytd","weight":0.1615}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"TuHURA Biosciences, Inc.是一家内华达州公司,成立于2009年6月24日,名称为Berry Only,Inc。该公司是一家临床阶段的生物制药公司。Kintara致力于为医疗需求未得到满足的患者开发新型癌症疗法。Kintara公司正在开发两种晚期疗法,以降低风险,满足明确的未满足的医疗需求。这两个项目分别是VAL-083治疗胶质母细胞瘤(GBM)和REM-001治疗皮肤转移性乳腺癌(CMBC)。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.09362},{"month":2,"riseRate":0.111111,"avgChangeRate":-0.150578},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.000318},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.030862},{"month":5,"riseRate":0.555556,"avgChangeRate":1.198143},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.040545},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.01467},{"month":8,"riseRate":0.5,"avgChangeRate":-0.086193},{"month":9,"riseRate":0.3,"avgChangeRate":-0.103258},{"month":10,"riseRate":0.4,"avgChangeRate":-0.116072},{"month":11,"riseRate":0.4,"avgChangeRate":-0.068131},{"month":12,"riseRate":0.2,"avgChangeRate":-0.2104}],"exchange":"NASDAQ","name":"TuHURA Biosciences, Inc.","nameEN":"TuHURA Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TuHURA Biosciences, Inc.(HURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供TuHURA Biosciences, Inc.(HURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"TuHURA Biosciences, Inc.,HURA,TuHURA Biosciences, Inc.股票,TuHURA Biosciences, Inc.股票老虎,TuHURA Biosciences, Inc.股票老虎国际,TuHURA Biosciences, Inc.行情,TuHURA Biosciences, Inc.股票行情,TuHURA Biosciences, Inc.股价,TuHURA Biosciences, Inc.股市,TuHURA Biosciences, Inc.股票价格,TuHURA Biosciences, Inc.股票交易,TuHURA Biosciences, Inc.股票购买,TuHURA Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TuHURA Biosciences, Inc.(HURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供TuHURA Biosciences, Inc.(HURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}